enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Bristol-Myers Squibb and Pfizer Announce Publication of ...

   www.aol.com/news/2013-05-06-bristol-myers-squibb...

   Bristol-Myers Squibb and Pfizer Announce Publication of ARISTOTLE Subanalysis in Circulation Subgroup analysis demonstrates that the treatment effects of Eliquis ® (apixaban) vs. warfarin, across ...

3. ELIQUIS® (apixaban) Demonstrates Consistent Reductions in ...

   www.aol.com/news/2012-10-01-eliquis-apixaban...

   The ARISTOTLE study was designed to demonstrate the efficacy and safety of ELIQUIS versus warfarin for the prevention of stroke or systemic embolism. In ARISTOTLE, 18,201 patients were randomized ...

4. Subanalysis of Phase III ARISTOTLE Trial of Eliquis ... - AOL

   www.aol.com/news/2013-09-03-subanalysis-of-phase...

   Subanalysis of Phase III ARISTOTLE Trial of Eliquis® (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart ...

5. Apixaban - Wikipedia

   en.wikipedia.org/wiki/Apixaban

   Apixaban is recommended by the National Institute for Health and Clinical Excellence for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation and at least one of the following risk factors: prior stroke or transient ischemic attack, age 75 years or older, diabetes, or symptomatic heart failure.

6. Direct thrombin inhibitor - Wikipedia

   en.wikipedia.org/wiki/Direct_thrombin_inhibitor

   Ximelagatran showed good efficacy compared with warfarin in several trials in prevention and treatment of deep vein thrombosis and as thromboprophylaxis in atrial fibrillation. [1] Development was stopped by manufacturer AstraZeneca , however, because of reports of liver enzyme derangements and liver failure .

7. Direct factor Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

   The monitoring of warfarin and keeping the international normalized ratio (INR) between 2.0 and 3.0, along with avoiding over and under treatment, has driven a search for an alternative. [ 3 ] [ 14 ] A naturally occurring inhibitor of factor Xa was reported in 1971 by Spellman et al. from the dog hookworm. [ 15 ]

8. U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the ... - AOL

   www.aol.com/news/2013-01-02-us-fda-approves...

   U.S. FDA Approves ELIQUIS ® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk Reductions Versus ...

9. Warfarin - Wikipedia

   en.wikipedia.org/wiki/Warfarin

   Warfarin is indicated for the prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism; [9] prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement; [9] and reduction in the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after ...